Galderma Group Ltd

Latest Results (17.12.2024):

Record Net Sales

In the first nine months of 2024, Galderma Group Ltd achieved record net sales of 3.259 billion USD, marking a 9.2% year-on-year growth at constant currency. This growth was primarily driven by volume increases and a favorable product mix, with all product categories and geographies contributing to the sales performance.

Injectable Aesthetics Growth

Galderma's Injectable Aesthetics segment reported net sales of 1,698 million USD for the first nine months of 2024, reflecting a 10.6% year-on-year growth at constant currency. Both sub-categories, Neuromodulators and Fillers, experienced double-digit growth, supported by strong demand in international markets and the U.S.

Dermatological Skincare Performance

The Dermatological Skincare segment achieved net sales of 990 million USD, growing by 10.6% year-on-year at constant currency. This growth was driven by flagship brands Cetaphil® and Alastin®, with particularly strong performance in international markets, offsetting lower consumer consumption in the U.S.

Therapeutic Dermatology Sales

Therapeutic Dermatology net sales reached 571 million USD, with a 2.9% year-on-year growth at constant currency. The growth was mainly fueled by international markets, despite a decline in the U.S. due to generic competition. The launch of Nemluvio® (nemolizumab) in the U.S. marked a significant milestone for this segment.

Full Year Outlook

Galderma Group Ltd has confirmed and narrowed its full-year net sales growth guidance to a range of 8.8-9.5% year-on-year at constant currency. The company expects its Core EBITDA margin to remain in line with 2023, driven by its Integrated Dermatology Strategy and strong commercial execution.